2 independently checked trend briefs about this subject, newest first.
headlinez.news detected 2 source-qualified news clusters connected to Ionis between July 9, 2026 and July 22, 2026. They span 1 newsroom category and average 6.5 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
Arrowhead Pharmaceuticals stock reaches five-year highs following successful Phase 3 trial results, while shares of competitor Ionis decline.
AstraZeneca and Ionis face market volatility following the failure of their heart disease drug, Wainua, in a critical clinical trial.